Cellectis

Regulatory Filings • Mar 2, 2016

PRESS RELEASE

Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility

New York, N.Y. – March 1st, 2016 – Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), announced today that its wholly owned subsidiary, Calyxt, Inc., has closed on the purchase of a 10-acre parcel in the St. Paul suburb of Roseville to build its new headquarters facility.

The new facility, which should be operational around mid-2017, will be comprised of a 35,000 square-foot office and lab building, with greenhouses and outdoor research plots.

Calyxt, Inc., is a Minnesota-based company focused on developing healthier food products to benefit both consumers and growers.

To find out more about Calyxt, please visit their website: www.calyxt.com

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-sciencefocused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

For further information, please contact:

Cellectis Jennifer Moore, VP Communications Phone: 917-580-1088 email: media@cellectis.com

Caitlin Kasunich KCSA Strategic Communications Phone: 212-896-1241 email: ckasunich@kcsa.com

Simon Harnest, VP Finance and Investor Relations Phone: 646-385-9008 email: simon.harnest@cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.